Related references
Note: Only part of the references are listed.Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program
Toshiaki Ohkuma et al.
DIABETES OBESITY & METABOLISM (2020)
High cardiovascular risk patients benefit more from bariatric surgery than low cardiovascular risk patients
David Gutierrez Blanco et al.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2019)
Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications
Michele Longo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study
Qiuhong Gong et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options
Caroline A. Andrew et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Separate and combined associations of obesity andmetabolic health with coronary heart disease: a pan-European case-cohort analysis
Camille Lassale et al.
EUROPEAN HEART JOURNAL (2018)
Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity
Sadiya S. Khan et al.
JAMA CARDIOLOGY (2018)
Cardiovascular Safety of Lorcaserin in Overweigh or Obese Patients
E. A. Bohula et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association Between Obesity and Cardiovascular Outcomes A Systematic Review and Meta-analysis of Mendelian Randomization Studies
Haris Riaz et al.
JAMA NETWORK OPEN (2018)
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum
William T. Cefalu et al.
DIABETES CARE (2018)
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Carel W. le Roux et al.
LANCET (2017)
Bariatric Surgery versus Intensive Medical Therapy for Diabetes-5-Year Outcomes
Philip R. Schauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mechanisms, Pathophysiology, and Management of Obesity
Steven B. Heymsfield et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction
Masaru Obokata et al.
CIRCULATION (2017)
Weight History and All-Cause and Cause-Specific Mortality in Three Prospective Cohort Studies
Edward Yu et al.
ANNALS OF INTERNAL MEDICINE (2017)
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors A Randomized Clinical Trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Low Adoption of Weight Loss Medications: A Comparison of Prescribing Patterns of Antiobesity Pharmacotherapies and SGLT2s
Catherine E. Thomas et al.
OBESITY (2016)
The changing face of diabetes complications
Edward W. Gregg et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Maximizing retention in long-term clinical trials of a weight loss agent: use of a dietitian support team
L. M. Delahanty et al.
OBESITY SCIENCE & PRACTICE (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials
Viktoria L. Gloy et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial
I. D. Caterson et al.
DIABETES OBESITY & METABOLISM (2012)
Anti-obesity drugs: past, present and future
R. John Rodgers et al.
DISEASE MODELS & MECHANISMS (2012)
Cardiovascular Risk Assessment in the Development of New Drugs for Obesity
William R. Hiatt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Bariatric Surgery and Long-term Cardiovascular Events
Lars Sjostrom et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Effect of the Look AHEAD Study Intervention on Medication Use and Related Cost to Treat Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
J. Bruce Redmon et al.
DIABETES CARE (2010)
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
Eric J. Topol et al.
LANCET (2010)
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Frank L. Greenway et al.
LANCET (2010)
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
W. Philip T. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
David J. Heal et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
A review and meta-analysis of the effect of weight loss on all-cause mortality risk
Mary Harrington et al.
NUTRITION RESEARCH REVIEWS (2009)
Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese patients Pooled 1-year data from the Rimonabant in Obesity (RIO) program
Luc Van Gaal et al.
DIABETES CARE (2008)
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Robin Christensen et al.
LANCET (2007)
Mechanisms linking obesity with cardiovascular disease
Luc F. Van Gaal et al.
NATURE (2006)
Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss - An update of the 1997 American Heart Association Scientific Statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism
P Poirier et al.
CIRCULATION (2006)
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies
C Barba et al.
LANCET (2004)
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
S Yusuf et al.
LANCET (2004)
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
L Sjöström et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
XENical in the prevention of diabetes in obese subjects (XENDOS) study
JS Torgerson et al.
DIABETES CARE (2004)
Bariatric surgery: A systematic review and meta-analysis
H Buchwald et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Minireview: Adiposity, inflammation, and atherogenesis
CJ Lyon et al.
ENDOCRINOLOGY (2003)
Treatment of obesity:: need to focus on high risk abdominally obese patients
JP Després et al.
BMJ-BRITISH MEDICAL JOURNAL (2001)
Intentional weight loss and mortality among overweight individuals with diabetes
DF Williamson et al.
DIABETES CARE (2000)
Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
K Fujioka et al.
DIABETES OBESITY & METABOLISM (2000)
Share Paper
